| Home > Publications Database > Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor-1 Receptor (CSF1R)-Related Disorder. |
| Journal Article | DZNE-2025-01151 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
Wiley
New York, NY
This record in other databases:
Please use a persistent id in citations: doi:10.1002/mds.30282
Abstract: Colony stimulating factor-1 receptor (CSF1R)-related disorder (CSF1R-RD) is an autosomal dominant, rapidly progressive, demyelinating disease leading to death usually within a few years. Because of the central role of CSF1R in microglia functions, allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested as a therapy for CSF1R-RD.To report multicenter clinical (Expanded Disability Scoring Scale [EDSS]), neurocognitive), neuroimaging (Sundal score), and biological (neurofilament light chain [NfL]) outcomes after HSCT in CSF1R-RD.We report an international cohort of 17 adult patients (8 females/9 males, 43.3 ± 9.4 years) who were treated in seven transplant centers. Patients were evaluated for a median of 2.5 years post-HSCT, including one patient with follow-up of 8 years. We also report neurological outcomes of the first child transplanted to date with biallelic CSF1R variants.In the first 6 months post-HSCT, 2 patients died from early complications of myeloablative transplantation, and clinical and radiological severity scores worsened in most surviving adult patients. At 12 months post-HSCT, most patients completely stabilized or improved in certain clinical domains. Radiological scores fully stabilized or slightly improved in all but one of the patients. Plasma/serum NfL sharply decreased in most patients after transplantation. Notably, 7/8 adult patients who received a reduced-intensity conditioning regimen displayed similar neurological outcomes as patients who underwent myeloablative transplantation.After an initial clinical and radiological deterioration in the first 6 months post-transplantation, HSCT can halt disease progression in patients with CSF1R-RD, regardless of their presenting clinical symptoms. The possibility of reduced conditioning regimens in CSF1R-RD opens the way to treat older patients. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Keyword(s): Humans (MeSH) ; Hematopoietic Stem Cell Transplantation: methods (MeSH) ; Male (MeSH) ; Female (MeSH) ; Adult (MeSH) ; Middle Aged (MeSH) ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor: genetics (MeSH) ; Cohort Studies (MeSH) ; Treatment Outcome (MeSH) ; Receptor, Macrophage Colony-Stimulating Factor (MeSH) ; CSF1R‐RD ; adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia ; demyelination ; hematopoietic stem cell transplantation ; neurofilament light chain ; neuroinflammation ; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor ; CSF1R protein, human ; Receptor, Macrophage Colony-Stimulating Factor
|
The record appears in these collections: |